Atgam 50 mg/ml 5 ml, 5 pcs.

Pharmgroup: MIBP-globulin.
Pharmaceutical effect: Immunosuppressive drug. Atgam® is a selective immunosuppressant that decreases the number of circulating thymus-dependent lymphocytes that form rosettes with ram red blood cells. This anti-lymphocytic action is thought to reflect a change in the function of the T-lymphocytes responsible for cellular immunity and involved in the humoral immune response. In addition to the anti-lymphocytic activity, Atgam® contains antibodies against other blood cells in small concentrations.
In rhesus and cynomolgus monkeys, Atgam® reduces the number of lymphocytes in thymus-dependent areas of the spleen and lymph nodes. When administered together with other immunosuppressive agents, such as antimetabolites and GCS, the formation of antibodies to equine gamma globulin in the patient is not significant.
Pharmacokinetics: When Atgam is prescribed in combination with other immunosuppressive agents, the half-life of equine IgG in plasma is 5.7±3 days.

Pharmacokinetics: When prescribed together with other immunosuppressive agents, the half-life of equine IgG in plasma is 5.7±3 days.

Indications

– For prevention of transplant rejection reactions in renal transplantation (when administered simultaneously with conventional therapy it increases the frequency of favorable outcomes during the rejection period);
– For delaying the first episode of transplant rejection reaction in renal transplantation (as addition to other methods of immunosuppressive therapy);
– treatment of aplastic anemia in the absence of indications for bone marrow transplantation (when administered in addition to standard maintenance therapy, Atgam may cause complete or partial hematological remission, improved survival in cases with proven or suspected immune etiology of the disease).

Active ingredient

Antithymocytic immunoglobulin

Composition

1 ampoule (5 ml) contains immunoglobulin antithymocytic (equine) 250 mg

How to take, the dosage

For intravenous infusion, the daily dose of Atgam is added to the dilution solution observing aseptic rules. The recommended dose is 10-20 mg daily for 8-14 days.

Special Instructions

For inpatient use only!

Contraindications

– hypersensitivity to the components of the drug;
– hypersensitivity to other preparations of horse serum.

Side effects

Cardiovascular system: arterial hypertension, arterial hypotension, tachycardia, pulmonary edema, decompensated heart failure, deep vein thrombosis, thrombophlebitis, vasculitis, renal artery thrombosis, nasal bleeding.
CNS and peripheral nervous system: headache, weakness, seizures, parasthesias, confusion, disorientation, movement coordination disorders, tremor, dizziness, muscle rigidity, sweating.
intestinal system: gastrointestinal bleeding/perforation, pain in epigastrium, stomach and abdominal area, abnormal liver function parameters.
intestinal system: hyperglycemia.
renal system: acute renal failure, enlarged/broken kidney.
Respiratory system: cough, laryngospasm, laryngeal edema, sore throat, stomatitis.
Blood system: neutropenia, granulocytopenia, aplasia, pancytopenia, hemolysis/hemolytic anemia, anemia, eosinophilia, lymphadenopathy.